A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00370383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy
Study identification
- NCT ID
- NCT00370383
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Agennix
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- Erlotinib Drug
- Satraplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 70 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2006
- Primary completion
- Jan 31, 2009
- Completion
- Feb 28, 2009
- Last update posted
- Aug 6, 2012
2006 – 2009
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Cancer Medical Center | Anaheim | California | 92801 | — |
| Scripps Clinic | La Jolla | California | 92037 | — |
| Kenmar Research Institute | Los Angeles | California | 90057 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| University of Miami Sylvester Cancer Center | Miami | Florida | 33136 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Highlands Oncology Group | Bentonville | Ohio | 72712 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Signal Point Hematology/Oncology | Middleton | Ohio | 45042 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19110 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00370383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2012 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00370383 live on ClinicalTrials.gov.